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Summary
 
The Rac1 guanine nucleotide exchange factor, Vav, is activated in hematopoietic cells in re-
sponse to a large variety of stimuli. The downstream signaling events derived from Vav have
been primarily characterized as leading to transcription or transformation. However, we report
here that Vav and Rac1 in natural killer (NK) cells regulate the development of cell-mediated
killing. There is a rapid increase in Vav tyrosine phosphorylation during the development of
antibody-dependent cellular cytotoxicity and natural killing. In addition, overexpression of
Vav, but not of a mutant lacking exchange factor activity, enhances both forms of killing by
NK cells. Furthermore, dominant-negative Rac1 inhibits the development of NK cell–medi-
ated cytotoxicity by two mechanisms: (
 
a
 
) conjugate formation between NK cells and target
cells is decreased; and (
 
b
 
) those NK cells that do form conjugates have decreased ability to po-
larize their granules toward the target cell. Therefore, our results suggest that in addition to
participating in the regulation of transcription, Vav and Rac1 are pivotal regulators of adhesion,
granule exocytosis, and cellular cytotoxicity.
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he Vav protooncogene, a multidomain protein ex-
pressed primarily in hematopoietic cells, is tyrosine
phosphorylated after the cross-linking of a number of cell
surface receptors. Although it was initially identified due to
a mutation which enables it to transform fibroblasts (1, 2),
it has become increasingly clear that Vav is an important
second messenger used by many receptors on hematopoi-
etic cells (3, 4). For example, Vav undergoes tyrosine phos-
phorylation after the cross-linking of many multisubunit
immune recognition receptors, including the B cell antigen
receptor, T cell antigen receptor, and Fc receptors (5–10).
Both Src family and Syk family protein tyrosine kinases
(PTKs)
 
1
 
 are involved in Vav phosphorylation (11–13). Ad-
ditional modular domains in Vav include two src homol-
ogy (SH)3 domains, an SH2 domain, a pleckstrin homol-
ogy domain, and a 
 
dbl
 
 homology domain, all of which
potentially facilitate its interaction with other second mes-
senger pathways (3, 4, 14). Recent analyses have focused
on the ability of Vav, through its 
 
dbl
 
 homology domain, to
act as a guanine nucleotide exchange factor (GEF) for the
Rho family low molecular weight GTPase, Rac1 (12, 13,
15, 16).
The Rho family of GTP-binding (G) proteins Rho,
Rac, and CDC42 has been implicated in regulating a num-
ber of cellular processes, including cytoskeletal alterations
(17), transcription factor regulation (18–21), cell-cycle pro-
gression (22, 23), and cellular transformation (24–27). Us-
ing genetic and biochemical approaches, RhoA and CDC42
have been associated with a number of receptor-initiated
events in hematopoietic cells, including Fc
 
e
 
RI-mediated
membrane ruffling in a basophilic leukemia cell line (28),
FcR-mediated phagocytosis by macrophages (29, 30), IL-8
receptor–induced integrin adhesion in lymphocytes (31),
and growth factor–dependent actin organization and cell
adhesion in macrophages (32). Furthermore, inactivation of
CDC42 in a CD4
 
1
 
 T cell hybridoma inhibits the polariza-
tion of the microtubule organizing center (MTOC) toward
the APC, and botulinum toxin–mediated inactivation of
 
1
 
Abbreviations used in this paper:
 
 ADCC, antibody-dependent cellular cyto-
toxicity; G protein, GTP-binding protein; GEF, guanine nucleotide ex-
change factor; KAR, killer cell–activating receptor; MTOC, microtubule
organizing center; OV, recombinant vaccinia virus encoding oncogenic-
Vav; PV, recombinant vaccinia virus encoding proto-Vav; PIP
 
2
 
, phos-
phatidylinositol 4,5 bisphosphate; PTK, protein tyrosine kinase; SH, src
homology; WR, wild-type vaccinia virus.
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RhoA in cytotoxic T cells and NK cells inhibits natural cy-
totoxicity toward sensitive target cells (33, 34). These ob-
servations indicate that certain Rho family G proteins are
involved in various specific leukocyte-mediated activation
events. However, it is unclear how these G proteins are ac-
tivated during receptor signaling, what GEFs are involved,
and whether the specific Rho family member Rac1 plays
any role in the generation of cell-mediated killing.
In this study, we have analyzed the role of Vav and its
downstream target, Rac1, in the regulation of NK cell–
mediated killing. NK cells represent a subpopulation of
lymphocytes that mediate lysis of virus-infected and tumor
cells through either natural cytotoxicity or Fc
 
g
 
RIIIA-medi-
ated antibody-dependent cellular cytotoxicity (ADCC; ref-
erence 35). Proximal signaling events initiated during
ADCC and natural cytotoxicity include both Src and Syk
family PTK activation (36–39). Vav is one of the proteins
that becomes rapidly tyrosine phosphorylated after FcR li-
gation, but its regulatory role in the generation of ADCC
or natural cytotoxicity remains unknown. We find that Vav
is tyrosine phosphorylated after the incubation of NK cells
with NK-sensitive target cells or with FcR-specific agonists.
In addition, overexpression of Vav results in enhanced kill-
ing, whereas a mutation in Vav which has been shown to
block its ability to mediate GTP for GDP exchange on
Rac1 abrogates this enhancement. Also, overexpression of
dominant-negative Rac1 inhibits NK cell–mediated cyto-
toxicity. NK cells expressing dominant-negative Rac1 have
a decreased ability to form conjugates with targets, and
those that do form conjugates have decreased ability to po-
larize their cytolytic granules toward the target cell. To-
gether, our data highlight a regulatory role for Vav and
Rac1 in the generation of cell-mediated killing.
 
Materials and Methods
 
Reagents, Antibodies, and Cells.
 
Unless otherwise noted, re-
agents were purchased from Sigma Chemical Co. (St. Louis, MO).
Antibodies used in these studies included anti-Vav polyclonal rab-
bit antisera (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
anti-FLAG murine mAb FLAG-M2 (Eastman Kodak Co., New
Haven, CT), antiphosphotyrosine mAb 4G10 (Upstate Biotech-
nology Inc., Lake Placid, NY), and goat anti–mouse IgG F(ab
 
9
 
)
 
2
 
(ICN Biomedicals, Inc., Aurora, OH). Purified anti-CD94 mAb
was isolated from the hybridoma HP-3B1 (provided by Miguel
Lopez-Botet, La Princesa Hospital, Autonomous University of
Madrid, Madrid, Spain) as described previously (40). Anti-Fc
 
g
 
RIII
mAb 3G8 (anti-CD16; reference 41) was purified by affinity chro-
matography over protein A–agarose. Cloned human NK cells were
isolated from the defibrinated peripheral blood of healthy donors as
described previously (42). The K562 human erythroid leukemia
cell line and the murine mastocytoma cell line P815 were obtained
from the American Type Culture Collection (Rockville, MD).
 
Recombinant Vaccinia Virus Generation and Infection.
 
Proto-Vav
(PV) and oncogenic-Vav (OV) cDNAs were excised from
pCDNA3 using HindIII and NotI (12), and then directionally
subcloned into the HindIII/NotI cloning site of pSHN11.
pSHN11 is a derivative of the original vaccinia virus expression
vector pSC11 (43). To tag the NH
 
2
 
-terminal end of Vav with the
FLAG amino acid sequence, a silent mutation was engineered
into the internal NcoI site of proto-Vav using the mutagenic
oligonucleotide 5
 
9
 
-CCCTGTGGTCGGCATGGGCAAGAT-
TTCGC-3
 
9
 
, the pSHN11 selection oligonucleotide 5
 
9
 
-CGA-
CGGGATCCCACGTGGAATTC-3
 
9
 
, and the transformer site-
directed mutagenesis kit from Clontech (Palo Alto, CA). Next,
the 5
 
9
 
 NcoI site encompassing the Vav start site was used to add
the FLAG amino acid sequence after digestion with NcoI and li-
gation of the phosphorylated and annealed NcoI FLAG-adaptor
oligonucleotides 5
 
9
 
-CATGGACTACAAGGACGACGATGA-
CAAGGC-3
 
9
 
 (
 
1
 
) and 5
 
9
 
-CATGGCCTTGTCATCGTCGTC-
CTTGTAGTC-3
 
9
 
 (
 
2
 
). The FLAG-tagged proto-Vav construct
containing the C464S mutation (FLAG.PV.C529S) was gener-
ated by subcloning a Pst1/Not1 fragment from the OV.C464S
construct into a Pst1/NotI-digested FLAG.proto-Vav vaccinia
vector. cDNAs encoding wild-type rac1, N17-rac1, wild-type
rhoA, and N19-rhoA were provided by J. Silvio Gutkind (Na-
tional Institute of Dental Research, National Institutes of Health,
Bethesda, MD; reference 18). The coding sequences were isolated
from pCDNA3 using BamHI and NotI, blunted using Klenow
fragment, and subcloned into the Sma1 cloning site of pSC11.
The cDNAs within the recombinant pSHN11 and pSC11 vectors
were then introduced into the WR strain of vaccinia via homolo-
gous recombination (44). Semipurified recombinant vaccinia virus
was used to infect cloned human NK cells (2 
 
3
 
 10
 
6 
 
cells/ml) for 1 h
in serum-free medium at a multiplicity of infection of 20:1. The
remainder of the infection (3–5 h) was carried out at 10
 
6 
 
cells/ml
in RPMI 1640 containing 10% bovine calf serum.
 
Cytotoxicity Assays.
 
The 
 
51
 
Cr-release assays were performed
as described previously (42). In all cases, spontaneous release did
not exceed 10% of maximum release. In redirected cytotoxicity
assays, NK clones were only able to lyse P815 target cells when
antibodies to specific NK cell triggering receptors were added.
Lytic units were calculated based on 20% cytotoxicity (45).
 
Immunoprecipitations and Immunoblot Analysis.
 
For experiments
in which NK cells were activated by target cells, 5 
 
3
 
 10
 
6
 
 cloned
NK cells were briefly pelleted with 2.5 
 
3
 
 10
 
6
 
 target cells and
then incubated at 37
 
8
 
C for the indicated period of time. In exper-
iments involving specific cell surface receptor cross-linking, 5 
 
3
 
10
 
6
 
 NK clones were incubated for 3 min on ice with either anti-
FcR mAb (3G8, 10 
 
m
 
g/ml) or anti-CD94 mAb (HP-3B1, 30
 
m
 
g/ml). Washed cells were then incubated with goat anti–mouse
IgG F(ab
 
9
 
)
 
2
 
 at 37
 
8
 
C for the indicated period of time. After stimu-
lation, the cells were lysed on ice for 10 min in 1 ml of buffer
containing 20 mM Tris-HCl, 40 mM NaCl, 5 mM EDTA, 50 mM
NaF, 30 mM Na
 
4
 
P
 
2
 
O
 
7
 
, 0.1% BSA, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM
PMSF, 5 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leupeptin, and 1% Triton
X-100. Cellular debris was removed by centrifugation at 14,000
rpm for 5 min at 4
 
8
 
C. FLAG-Vav or endogenous Vav were im-
munoprecipitated from the lysate for 1–2 h at 4
 
8
 
C using 5 
 
m
 
g of
anti–FLAG-M2 mAb bound to goat anti–mouse IgG–agarose beads,
or 5 
 
m
 
g of anti-Vav rabbit antisera bound to protein A–Sepharose
beads, respectively. Protein complexes were washed four times in
wash buffer (lysis buffer lacking BSA). Bound proteins were then
eluted in 40 
 
m
 
l of SDS-sample buffer, resolved by SDS-PAGE,
and transferred to Immobilon-P membranes (Millipore Corp.,
Bedford, MA). Tyrosine-phosphorylated proteins were detected
using the 4G10 mAb, followed by sheep anti–mouse IgG coupled
to horseradish peroxidase (Amersham International, Little Chal-
font, Buckinghamshire, UK) and the ECL detection system (Am-
ersham International). Vav was detected using specific rabbit anti-
sera to Vav, followed by protein A–horseradish peroxidase
(Amersham International) and the ECL detection system. 
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Conjugate Analysis.
 
Quantification of effector–target conju-
gates was performed as described previously (46). In brief, NK
cells were labeled intracellularly for 1 h at 37
 
8
 
C with 100 
 
m
 
M sul-
fofluorescein (Molecular Probes, Inc., Eugene, OR), and the
K562 target cells were labeled intracellularly for 1 h at 37
 
8
 
C with
40 
 
m
 
g/ml of hydroethidine (Polysciences Inc., Warrington, PA).
The washed cells were then resuspended at a concentration of
5 
 
3
 
 10
 
6
 
 cells/ml. The effectors and targets (25 
 
m
 
l of each) were
mixed together, pelleted, and allowed to incubate at 37
 
8
 
C for 10
min. The pellet was gently resuspended and transferred to 1 ml of
ice-cold RPMI 1640 medium. Conjugate formation (simulta-
neous green and red fluorescence) was quantitated using a FACS-
can
 
Ò
 
 (Becton Dickinson, San Jose, CA). Results are expressed as
the percentage of total NK cells that formed conjugates.
 
Granule Polarization Assay.
 
The cytoplasmic granules of in-
fected NK cells were labeled with acridine orange (5 
 
m
 
l, 1 mg/ml;
Polysciences Inc.) for 30 min at 37
 
8
 
C in the dark. The cells were
washed four times in PBS containing 1% BSA and resuspended in
the same buffer at a concentration of 2 
 
3
 
 10
 
7
 
 cells/ml. K562
target cells were washed in PBS containing 1% BSA and then re-
suspended at a final concentration of 10
 
7
 
 cells/ml. Equal volumes
(50 
 
m
 
l) of effector and target cells were briefly pelleted and then
incubated at 37
 
8
 
C in the dark for 10 min. The pellets were gently
resuspended, and 30 
 
m
 
l was placed on each slide. NK cells that had
formed conjugates were assessed for granule polarization using a
fluoromicroscope (Carl Zeiss, Jena, Germany). A total of 100 con-
jugates was evaluated per slide, and the evaluation was performed
by an individual blinded to the various treatment groups.
 
Results
 
Vav Is Tyrosine Phosphorylated during the Generation of Cel-
lular Cytotoxicity.
 
Src family and Syk family tyrosine ki-
nases provide early and requisite signals during the genera-
tion of NK cell–mediated killing. However, it has been
difficult to determine the precise identities of tyrosine-
phosphorylated substrates that regulate natural killing be-
cause a single prototypic triggering molecule on the NK
cell has not been identified. Consistent with a previous re-
port (10), Vav becomes tyrosine phosphorylated after FcR
cross-linking on NK cells (Fig. 1 
 
A
 
). However, since it has
been previously observed that different intracellular signals
can be required for the generation of ADCC and natural
killing (47), we wanted to determine if Vav is activated
during natural killing. To do this, we generated a recombi-
nant vaccinia virus encoding a FLAG-tagged proto-Vav
(FLAG-Vav), which we used to selectively infect the NK
effector cells. This allows us to distinguish Vav protein de-
rived from NK cells from that of NK-sensitive target cells.
Human NK cells were infected with the recombinant
FLAG-Vav virus and then incubated with the prototypic
NK cell target, K562. The cells were lysed, and recombi-
nant FLAG-Vav protein was specifically immunoprecipi-
tated using the anti-FLAG mAb and analyzed for tyrosine
phosphorylation. As shown in Fig. 1 
 
B
 
, Vav undergoes a
time-dependent increase in tyrosine phosphorylation dur-
ing the incubation with target cells, peaking at 2 min and
decreasing to background levels by 10 min. This increase in
Vav tyrosine phosphorylation is also seen when endoge-
nous Vav is immunoprecipitated from [
 
32
 
P]orthophos-
phate-labeled NK cells after target cell incubation, as deter-
mined by autoradiography and phosphoamino acid analysis
(Billadeau, D.D., C.J. Dick, and P.J. Leibson, unpublished
observation). Furthermore, Vav becomes tyrosine phos-
phorylated after the incubation with other NK-sensitive
targets such as the class I–deficient B lymphoblastoid cell
lines 721 and CIR (data not shown). To determine if Vav
activation is linked to specific killer cell–activating recep-
tors (KARs), we analyzed a human NK clone that under-
goes activation and killing of target cells upon cross-linking
of the CD94–NKG2 complex on the cell surface (48). In-
deed, cross-linking of the CD94–NKG2-activating com-
plex on these NK clones results in a time-dependent in-
crease in Vav tyrosine phosphorylation, peaking between 1
and 2 min and decreasing to background levels by 5 min
(Fig. 1 
 
C
 
). Together, these data suggest that the activation
of Vav, as measured by tyrosine phosphorylation, appears
to be an integral part of signaling pathways activated by
FcR cross-linking, CD94–NKG2-activating receptor cross-
linking, and natural cytotoxicity.
 
Vav Overexpression Enhances Cell-mediated Cytotoxicity.
 
The above data identify Vav as a signaling molecule that is
biochemically altered during cell-mediated killing, but its
role in regulating this process is unclear. It is conceivable
that the only role for Vav is the regulation of transcription
factors required for gene expression after NK cell activa-
tion. However, it is also possible that it plays a more imme-
diate role in the generation of the cytotoxic response itself.
To test this possibility, we evaluated cytotoxicity using NK
Figure 1. Vav is tyrosine phos-
phorylated during natural killing and
after KAR cross-linking. (A) Vav
was immunoprecipitated from 5 3
106 NK cells after 1 min of FcR
cross-linking with anti-FcR 3G8
mAb (a-FcR). (B) NK cells were in-
fected with vaccinia virus expressing
the FLAG-Vav construct. Using
anti-FLAG mAb, viral expressed
FLAG-Vav was immunoprecipi-
tated from 5 3 106 NK cells which
had been incubated at 378C for the indicated times (in minutes) with
2.5 3 106 K562 cells. (C) Vav was immunoprecipitated from 5 3 106 NK
cells after cross-linking of the activating CD94–NKG2 complex for the
indicated times (in minutes) at 378C. In all cases, the immunoprecipitates
were resolved by SDS-PAGE, transferred to a nylon membrane, and
probed with either antiphosphotyrosine mAb (upper panels, a-p-Tyr) or
anti-Vav polyclonal rabbit sera (lower panels, a-vav). This is a representa-
tive example from three separate experiments. 
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clones which had been infected with vaccinia virus express-
ing proto-Vav (PV), oncogenic-Vav (OV), or a mutant of
proto-Vav (PV.C529S), which should putatively inhibit
GEF activity (12). To determine if Vav is involved in regu-
lating natural killing, we infected human NK clones with the
different Vav-encoding recombinant vaccinia. Infection of
NK clones with proto-Vav results in a significant increase in
killing of the K562 target cells compared with cells infected
with the wild-type virus alone (WR; Fig. 2 
 
A
 
,
 
 P 
 
,0.005),
whereas infection with oncogenic-Vav or the inactive
proto-Vav mutant does not enhance natural killing com-
pared with WR-infected clones (Fig. 2 A). In addition, using
reverse ADCC and the Fc-bearing P815 target cell line, we
found that Vav is involved in the regulation of cytotoxicity
initiated through the FcR, and through the activating
CD94–NKG2 complex on NK clones (Fig. 2, B and C). As
observed with natural cytotoxicity, proto-Vav significantly
enhanced killing initiated by either of these receptor com-
plexes (P ,0.005 for each receptor), whereas expression of
the inactive proto-Vav or oncogenic-Vav proteins had no
effect (Fig. 2, C and D). The ability of proto-Vav to enhance
cell-mediated cytotoxicity through natural killing or reverse
ADCC was not unique to NK cells, as similar results were
found after overexpression of the various Vav constructs in
cloned human CD81 cytotoxic T cells using anti-CD3 stim-
ulation in a reverse ADCC assay (Billadeau, D.D., and P.J.
Leibson, unpublished observations). The ability of proto-
Vav, but not the inactive proto-Vav, or oncogenic-Vav to
enhance NK clone killing was not due to differences in pro-
tein expression levels, since all recombinant proteins were
equivalently expressed as determined by immunoblotting
(data not shown). Taken together, these data suggest that
Vav is involved in regulating the NK cell cytolytic machin-
ery during the generation of natural killing, FcR-mediated
killing, and killing initiated by KAR cross-linking. Further-
more, since the oncogenic-Vav C464S (identical to C529S
in proto-Vav) mutation has been previously shown to inhibit
GTP®GDP exchange on Rac1, it is likely that Vav regu-
lates, at least in part, cell-mediated cytotoxicity by enhancing
Rac1 activation.
Rac1 Regulates NK Cell-mediated Cytotoxicity. Based on
the observations that Vav is involved in regulating NK cell
killing of target cells and that it is a known GEF for Rac1,
we next investigated if Rac1 is involved in the generation
of cell-mediated cellular cytotoxicity in NK cells. We as-
sessed NK cell–mediated killing in NK clones infected with
recombinant vaccinia virus expressing wild-type Rac1,
RhoA, or dominant-negative versions of Rac1 (N17rac1)
and RhoA (N19rhoA). It has previously been observed
that inactivation of RhoA protein by ADP-ribosylation us-
ing C3 exoenzyme inhibits NK and CTL killing of target
cells (33). Therefore, we used N19rhoA as a control for in-
hibition in our 51Cr-release assays. Indeed, expression of
N19rhoA in NK clones significantly inhibited killing of the
K562 target cells during natural killing compared with WR
(P ,0.005), whereas wild-type rhoA had no effect (Fig. 3 A).
Expression of N17rac1 in NK clones also significantly
inhibited killing of K562 (Fig. 3 A, P ,0.005) or killing
initiated either through the FcR or the activating CD94–
NKG2 complex (Fig. 3, B and C, P ,0.005 for both
receptors). The inhibition of killing observed with domi-
nant-negative Rac1 and RhoA was also observed in cloned
human cytotoxic T cells after CD3 cross-linking in a re-
verse ADCC assay (Billadeau, D.D., and P.J. Leibson, un-
published observations). These data suggest that Rac1, one
of the targets of Vav, regulates cell-mediated cytotoxicity
initiated by a variety of “triggering” receptors.
Conjugate Formation between NK Clones and Target Cells Is
Inhibited by Overexpression of Dominant-negative Rac1. The for-
mation of a stable conjugate between an NK cell and its
potential target cell is required for granule polarization and
the generation of cell-mediated cytotoxicity. It is possible
that dominant-negative Rac1 is affecting the ability of the
NK cell to kill the target by interfering with formation of
stable conjugates or by inhibiting granule polarization. To
determine if NK clones expressing dominant-negative
Rac1 were affected in their ability to form conjugates, we
labeled uninfected or infected NK cells intracellularly with
sulfofluorescein, and labeled K562 target cells intracellularly
with hydroethidine. Using two-colored flow cytometry,
we analyzed the NK cells (green fluorescence) for their
ability to form conjugates with K562 (red fluorescence).
Conjugates were scored based on simultaneous emission of
both green and red fluorescence, and the results are ex-
Figure 2. Vav is involved in cell-mediated cytotoxicity. NK clones were infected with the indicated recombinant vaccinia virus. Infected NK clones
were incubated with 51Cr-labeled K562 (A), P815 cells coated with 0.15 mg/ml of the anti-FcR mAb 3G8 (B), or P815 cells coated with 0.15 mg/ml of
the anti-CD94 mAb HP-3B1 (C). This is a representative example of eight separate experiments. Data are expressed as lytic units/106 cells 6 1 SD.553 Billadeau et al.
pressed as the percentage of total NK cells that formed con-
jugates. In all experiments, 51Cr-release assays were per-
formed as controls to measure inhibition and enhancement
of killing by the infected NK clones (data not shown). In-
fection of NK clones with wild-type vaccinia virus (WR)
did not significantly affect their ability to form conjugates
compared with uninfected cells (Fig. 4, and data not
shown). Although we consistently observed an enhanced
killing of target cells by NK clones overexpressing proto-Vav
(see Fig. 2, A–C), we never observed a significant increase in
the percentage of NK clones forming conjugates compared
with cells infected with WR (see Fig. 4). However, we did
consistently observe a significant decrease in the number of
conjugates formed by NK cells overexpressing the domi-
nant-negative N17rac1. RhoA has previously been impli-
cated in influencing LFA-1–dependent adhesion (31).
Therefore, as a positive control, we also tested the influence
of dominant-negative N19rhoA. Similar to N17rac1,
N19rhoA significantly inhibited conjugate formation (Fig.
4). These data suggest that at least for N17rac1 and
N19rhoA, one mechanism by which they inhibit NK clone
killing of a target cell during natural killing is by decreasing
the formation of a stable effector to target cell interaction.
NK Cells Expressing Dominant-negative Rac1 Have a De-
creased Ability to Polarize Granules after Conjugate Forma-
tion. Directed delivery of granule components to the tar-
get cell is controlled by actin polymerization and formation
of an MTOC. Since Rac1 and RhoA have been implicated
as major regulators of the actin cytoskeleton in other cell
types, it is possible that N17rac1 and N19rhoA may also be
working at the level of granule polarization to inhibit kill-
ing. In addition, proto-Vav, which we have consistently
found to significantly enhance killing, does not appear to
enhance conjugate formation but may be involved in en-
hancing granule polarization. Therefore, we analyzed the
effects of these proteins on granule polarization, as this is a
requisite step in cell-mediated cytotoxicity. Since neither
N17rac1 nor N19rhoA completely blocks conjugate for-
mation, we directly analyzed NK cells and target cells that
had formed conjugates to determine if they had polarized
their granules toward the target cell. Acridine orange is a
weak base that can cross plasma membranes and is taken up
rapidly into acidic granules. Once inside NK cells, this flu-
orochrome becomes protonated and trapped within the cy-
tolytic granules, where it fluoresces red (49). The fluores-
cent granules can be visualized within the cells using
fluorescence microscopy, and the position of the granules
within the cell in relation to the target cell can be observed.
In nonconjugated NK cells, the granules are located dif-
fusely throughout the cytoplasm. However, once a stable
conjugate is formed and the cytolytic machinery is acti-
vated, the MTOC forms, and the granules become posi-
tioned adjacent to the target cell. The upper panel of Fig. 5
shows a confocal microscopic image of an acridine orange–
labeled NK clone conjugated to the K562 target cell in
which the granules of the NK cell are not polarized toward
the target, but remain diffusely located throughout the cy-
toplasm. The lower panel of Fig. 5 shows a conjugate
where the granules of the NK cell have polarized toward
the target cell. To determine if the dominant-negative
Rac1 and RhoA proteins are affecting granule polarization,
we infected NK clones with the recombinant viruses indi-
cated in Table 1, labeled their cytolytic granules with acri-
dine orange, incubated them with the K562 target cell, and
then using fluorescence microscopy scored the number of
Figure 3. Rac1 regulates cell-mediated cytotoxicity. NK clones were infected with the indicated recombinant vaccinia virus. Infected NK clones were
incubated with 51Cr-labeled K562 (A), P815 cells coated with 0.15 mg/ml of the anti-FcR mAb 3G8 (B), or P815 cells coated with 0.15 mg/ml of the
anti-CD94 mAb HP-3B1 (C). This is a representative example of eight separate experiments. Data are expressed as lytic units/106 cells 6 1 SD.
Figure 4. Dominant-negative Rac1 inhibits conjugate formation. NK
clones infected with the indicated recombinant vaccinia virus were
stained intracellularly with sulfofluorescein (green fluorescence), and then
incubated for 10 min at 378C with K562 target cells which had been
stained intracellularly with hydroethidine (red fluorescence). Using flow
cytometry, the percentage of NK cells forming conjugates were scored
based on the simultaneous emission of both green and red fluorescence.
104 events were analyzed per sample. The data presented are a representa-
tive example of five different experiments.554 Regulation of Cell-mediated Cytotoxicity by the Vav–Rac1 Pathway
Figure 5. Visualization of acridine orange–stained granules in NK cells by fluorescence microscopy. Acridine orange–labeled NK clones were incu-
bated with K562 target cells as described in Materials and Methods. After this incubation, the cells were placed on a slide, and the fluorescent granules
were observed using fluorescence microscopy. (Top) Representative example of a conjugate in which the cytolytic granules of the NK cell have not po-
larized with respect to the K562 target cell. (Bottom) Conjugate in which the granules in the NK cell have been polarized toward the K562 target cell.
Scale: 0.1 mM/1 pixel; picture width 5 512 pixels).555 Billadeau et al.
conjugates containing polarized granules. Simultaneously,
51Cr-release assays were performed as a measure of en-
hancement and inhibition of killing by the infected NK
clones (data not shown). In each experiment (Table 1), we
observed an increase in granule polarization of NK clones
overexpressing proto-Vav. This parallels our finding that
proto-Vav overexpression enhances cell-mediated cytotox-
icity (see Fig. 2, A–C). Similar to our findings in 51Cr-release
assays, expression of PV.C529S abrogates granule polariza-
tion compared with proto-Vav, suggesting that it requires
its GEF activity in order to enhance killing. Interestingly,
overexpression of N17rac1 and N19rho results in a decrease
in granule polarization of NK cells that have formed conju-
gates compared with WR, which is consistent with their
ability to inhibit killing (see Fig. 3 A). These data suggest
that Vav and Rac1 can potently regulate cell-mediated kill-
ing by influencing granule polarization in NK cells which
have bound to susceptible targets.
Discussion
The killing of virus-infected or tumor target cells by
CTLs is a tightly regulated process involving receptor–
ligand interactions between the CTL and the target cell,
and the subsequent activation of multiple biochemical sig-
naling pathways. In this study, we have provided both bio-
chemical and genetic evidence that the Vav–Rac1 pathway
regulates cell-mediated killing by CTLs. We found that the
GEF Vav is tyrosine phosphorylated during ADCC and
natural killing, and that overexpression of proto-Vav en-
hances cell-mediated killing, whereas expression of inactive
proto-Vav or oncogenic-Vav has no effect on the killing of
target cells. Vav has been previously shown to facilitate
Rac1 activation (12). This suggests that Rac1 is a potential
downstream target involved in the regulation of cell-medi-
ated killing. Indeed, overexpression of dominant-negative
Rac1 inhibits killing of target cells during ADCC and nat-
ural cytotoxicity. Furthermore, we show that overexpres-
sion of dominant-negative Rac1 abrogates conjugate for-
mation, and that those NK cells that do form conjugates
have a decreased ability to polarize their cytolytic granules
toward the target cell. Taken together, our data highlight a
novel role for the Vav–Rac1 pathway that is distinct from
its known role as a regulator of transcriptional activation.
It is clear that the proximal activation of PTKs is a criti-
cal and requisite step in the development of cell-mediated
cytotoxicity (37–39), and that Vav is phosphorylated by
both Src and Syk family PTKs after the cross-linking of
many multisubunit immune receptors (11–13, 50, 51). In
NK cells, we have found that Vav is a target of activated
PTKs during natural killing as well as cross-linking of the
activating CD94–NKG2 complex and FcgRIIIA (see Fig.
1, A–C), but the precise identity of the PTK(s) involved in
its phosphorylation remains unknown. NK cells express
many Src family PTKs, including Lck, Fyn, and Lyn, as
well as both Syk family PTKs, ZAP-70 and Syk. Both Src
and Syk family kinases are activated after cross-linking of
FcgRIIIA (52–57) and CD94–NKG2 (40, 48), and we
have recently shown that Syk is activated during natural
killing (36). Among the predicted Vav SH2 domain bind-
ing sites (58), there are YESP motifs in Syk at position
Y348 and in ZAP-70 at position 315. These tyrosines are
required for the physical interaction of the Vav SH2 do-
main with the Syk family PTKs and also for the activation
of Vav (50, 59–61). Since Syk is activated during natural
killing and ADCC, it might be predicted that mutation of
Y348F in Syk would impact Vav activation. Furthermore,
mutation at the critical amino acid R696 in the Vav SH2
domain, which has been shown to inhibit Vav tyrosine
phosphorylation (62) and subsequent Vav activity (59, 60),
should negatively impact cell-mediated cytotoxicity when
overexpressed in NK cells. Additional studies will be
needed to test these predictions.
Our observation that overexpression of Vav results in
enhanced cell-mediated cytotoxicity parallels results ob-
tained in T cells where overexpression of Vav results in a
synergistic increase in nuclear factor of activated T cells
(NFAT)-dependent and NFIL-2–dependent transcription
after TCR cross-linking (63). However, although expres-
sion of oncogenic-Vav, which is missing the first 65 amino
acids at the NH2 terminus of the protein, is oncogenic in
NIH 3T3 fibroblasts (1), its expression does not result in a
synergistic increase in transcriptional activation (63). Simi-
larly, we found that expression of oncogenic-Vav in NK
clones does not enhance NK cell killing (Fig. 2, A–C), sug-
gesting that the NH2 terminus of Vav is somehow required
to get full Vav activity in normal hematopoietic cells. It has
been reported that the NH2-terminal region of Vav con-
tains a potential helix-loop-helix domain followed by a
leucine zipper (1, 2). However, recent protein alignment
studies have suggested that this domain is more similar to a do-
main found in the F-actin binding protein, calponin (64). This
is intriguing, as Vav has been found to associate with other
proteins involved in cytoskeletal organization, such as tubulin
(65) and zyxin (66). We have observed that both proto-Vav
and oncogenic-Vav become tyrosine phosphorylated in a sim-
ilar time-dependent fashion after FcR cross-linking (Fig. 1 A,
Table 1. NK Cell Granule Polarization Is Regulated by Vav and 
Rho Family G Proteins
NK cell infection
with recombinant
vaccinia virus Exp. 1 Exp. 2 Exp. 3
polarized/total*
WR 58/100 52/100 51/100
PV 82/100 77/100 76/100
PV.C529S 53/100 54/100 48/100
N17rac1 27/100 28/100 22/100
N19rhoA 31/100 35/100 29/100
Exp., Experiment.
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and data not shown). Therefore, it is possible that the inter-
action of Vav with cytoskeletal constituents after its activa-
tion might serve to localize Vav in a particular compart-
ment where it can then activate its downstream effectors
such as Rac1. Furthermore, since Vav has been found to
associate with a number of signaling molecules through its
SH2, SH3, and proline-rich regions (for a review, see ref-
erence 3), it is possible that incorrect localization of these
proteins when bound to oncogenic-Vav results in non-
functional signaling complexes. Interestingly, as shown in
Fig. 2, A–C, overexpression of PV.C529S, which puta-
tively lacks GEF activity (12), does not lead to enhanced
target cell killing. Taken together, these results suggest that
in order for Vav to enhance killing, it must have GEF ac-
tivity, and it must retain structural determinants in its NH2
terminus to be correctly localized during its activation.
The importance of Vav in T and B cell antigen recep-
tor–mediated signal transduction was previously defined
using the recombination activating gene (RAG)-12/2 blas-
tocyst complementation technique and Vav-deficient em-
bryonic stem cells (67–69). Those authors observed that in
the absence of Vav, there was an overall decrease in the
number of peripheral T cells and subpopulations of B cells,
and both mature populations of cells had severe defects as-
sociated with antigen receptor signaling. The role of Vav in
other cells of the immune system was not evaluated due to
the observed embryonic lethality of these Vav-deficient
mice (67–69). However, recent experiments have demon-
strated that Vav-deficient mice are viable, and that Vav is
involved in both the positive and negative selection of
thymocytes (70). Data on NK cell function in these Vav-
deficient mice have not been reported. Interestingly, in
response to TCR stimulation, Vav-deficient thymocytes have
a decreased ability to mobilize intracellular Ca21 (70), a criti-
cal second messenger required for NK cell–mediated killing
by ADCC and natural killing (42, 71). Furthermore, it has
been demonstrated that the targets of Vav activation, the Rho
family of GTPases, activate phosphatidylinositol 4-phosphate
5-kinase, leading to an increase in phosphatidylinositol 4,5
bisphosphate (PIP2; references 72–74). PIP2 is a known sub-
strate for phospholipase C, which is activated during FcR
cross-linking on NK cells (56, 75), and results in the subse-
quent release of intracellular Ca21 after the generation of
inositol 3,4,5 trisphosphate. Additionally, PIP2, which has
been shown to interact and modulate the function of a num-
ber of cytoskeleton-associated proteins (76–78), may directly
influence cytoskeletal reorganization during the generation of
cell-mediated killing. Data on phosphoinositide metabolism
and calcium signaling in NK cells with impaired Rho family
G protein function have not been reported.
The Rho family of G proteins was initially identified as
regulating the cytoskeleton, including the formation of
stress fibers, membrane ruffles, filopodia, and lamellipodia
(for a review, see reference 17). Our data clearly indicate
that in CTLs, Rac1 is involved in the regulation of granule
exocytosis initiated by cross-linking of activating receptors
(see Fig. 3, A–C). It was previously observed using phar-
macologic inhibition of RhoA with C3 exoenzyme that
RhoA is involved in the generation of cell-mediated killing
(33). Using a genetic approach, we found that expression of
a dominant-negative form of RhoA (N19rhoA) also inhib-
its killing elicited through activating receptors. In addition,
although we have not tested whether CDC42 is involved
in NK cell–mediated killing, it has been shown in a T cell
line that expression of dominant-negative CDC42 inhibits
MTOC formation after binding to APCs (34). These data
suggest that in lymphocytes, cytoskeletal rearrangements
and granule exocytosis are controlled in part through the
activation of multiple Rho family members (i.e., Rac1,
CDC42, and RhoA). However, it remains unclear whether
these proteins serve overlapping functions during granule
exocytosis, or if they regulate separate portions of the in-
volved signaling pathways. Indeed, different Rho family
members have been observed to control various aspects of
the actin cytoskeleton and also to influence activation of
the other family members (79, 80).
The Rho family of G proteins has been shown to regu-
late events in leukocytes that require rearrangement of the
cytoskeletal network, including FcR-induced phagocytosis
by macrophages (29, 30), degranulation in mast cells (28),
and monocyte spreading (81, 82). Interestingly, inhibition
of RhoA function in macrophages with C3 exoenzyme in-
hibits Ca21 signaling through the FcR, and the clustering
of receptors in response to opsonin, both of which are crit-
ical steps in FcR-induced signaling and phagocytosis (30).
Moreover, cadherin is a Ca21-dependent adhesion mole-
cule involved in cell–cell interactions, and its ability to in-
teract with the actin cytoskeleton is inhibited by expression
of dominant-negative Rac1 and RhoA (83). Cell–cell con-
tacts and the aggregation of activated receptors are required
for the development of cell-mediated cytotoxicity. Indeed,
humans and mice lacking the b2-containing integrin LFA-1
(CD11a/CD18) have deficient NK cell function (84, 85).
Although we observed a significant inhibition of conjugate
formation in NK cells expressing N17rac1 and N19rhoA,
we did not observe a significant increase in conjugate for-
mation in cells overexpressing proto-Vav (see Fig. 4). It is
possible that although expression of the inactive proteins
does not completely interfere with conjugate formation, it
compromises the quality of the cell–cell contact and thereby
influences the development of cell-mediated killing. The
granule polarization studies demonstrate that conjugates are
formed with cells expressing the dominant-negative pro-
teins, but the majority of these cells fail to polarize their
granule toward target cells (see Table 1). In addition,
whereas overexpression of proto-Vav leads to an increase
in cell-mediated killing, it has no impact on conjugate for-
mation. However, the data from Table 1 suggest that over-
expression of proto-Vav results in an increase in the num-
ber of conjugates in which the NK cells have polarized
their granule toward the target cell. Therefore, it is possible
that proto-Vav does not increase the overall adhesion be-
tween the two cells, but influences more directly the ma-
chinery involved in granule polarization.
Our data suggest that the GEF Vav, a target of PTKs af-
ter activation through a variety of cell-surface receptors on557 Billadeau et al.
NK cells, and its target, Rac1, are involved in the regula-
tion of granule exocytosis in CTLs. These results suggest a
novel role for Vav distinct from its ability to act as a regula-
tor of transcription factors. In addition, our results provide
insight into how the engagement of ligands on the cell sur-
face of CTLs can control the development of cell-mediated
killing through the activation of Rho family GTPases. This
experimental system can now be used to evaluate proximal
interactions influencing Vav–Rac1 activation and the
downstream effectors critical for the generation of effective
cell-mediated cytotoxicity.
This research was supported by the Mayo Foundation and by National Institutes of Health grant CA-47752.
D.D. Billadeau is supported by National Institutes of Health Postdoctoral Training Grant CA-09441, and
X.R. Bustelo is a Sinsheimer Scholar whose work is supported by grant CA-7373501.
Address correspondence to Paul J. Leibson, Department of Immunology, Mayo Clinic, 200 First St., Roch-
ester MN 55905. Phone: 507-284-4563; Fax: 507-284-1637; E-mail: leibson.paul@mayo.edu
Received for publication 24 March 1998 and in revised form 19 May 1998.
References
1. Katzav, S., D. Martin-Zanca, and M. Barbacid. 1989. Vav, a
novel human oncogene derived from a locus ubiquitously
expressed in hematopoietic cells. EMBO (Eur. Mol. Biol. Or-
gan.) J. 8:2283–2290.
2. Katzav, S., J.L. Cleveland, H.E. Heslop, and D. Pulido. 1991.
Loss of the amino-terminal helix-loop-helix domain of the
vav proto-oncogene activates its transforming potential. Mol.
Cell. Biol. 11:1912–1920.
3. Bustelo, X.R. 1996. The VAV family of signal transduction
molecules. Crit. Rev. Oncog. 7:65–88.
4. Collins, T., M. Deckert, and A. Altman. 1997. Views on
Vav. Immunol. Today. 18:221–225.
5. Bustelo, X.R., J.A. Ledbetter, and M. Barbacid. 1992. Prod-
uct of the vav proto-oncogene defines a new class of tyrosine
protein kinase substrates. Nature. 356:68–71.
6. Bustelo, X.R., and M. Barbacid. 1992. Tyrosine phosphory-
lation of the vav proto-oncogene product in activated B cells.
Science. 256:1196–1199.
7. Darby, C., R.L. Geahlen, and A.D. Schreiber. 1994. Stimu-
lation of macrophage FcgRIIIA activates the receptor-associ-
ated protein tyrosine kinase Syk and induces phosphorylation
of multiple proteins including p95Vav and p62/GAP-associ-
ated protein. J. Immunol. 152:5429–5437.
8. Kiener, P.A., B.M. Rankin, A.L. Burkhardt, G.L. Schiven,
L.K. Gilliland, R.B. Rowley, J.B. Bolen, and J.A. Ledbetter.
1993. Cross-linking of Fcg receptor I (FcgRI) and receptor
II (FcgRII) on monocytic cells activates a signal transduction
pathway common to both Fc receptors that involves the
stimulation of p72 Syk protein tyrosine kinase. J. Biol. Chem.
268:24442–24448.
9. Margolis, B., P. Hu, S. Katzav, W. Li, J.M. Oliver, A. Ull-
rich, A. Weiss, and J. Schlessinger. 1992. Tyrosine phosphor-
ylation of vav proto-oncogene product containing SH2 do-
main and transcription factor motifs. Nature. 356:71–74.
10. Xu, X., and A.S. Chong. 1996. Vav in natural killer cells is
tyrosine phosphorylated upon cross-linking of FcgRIIIA and
is constitutively associated with a serine/threonine kinase.
Biochem. J. 318:527–532.
11. Costello, P.S., M. Turner, A.E. Walters, C.N. Cunningham,
P.H. Bauer, J. Downward, and V.J.L. Tybulewicz. 1996.
Critical role for the tyrosine kinase Syk in signaling through
the high affinity IgE receptor on mast cells. Oncogene. 13:
2595–2605.
12. Crespo, P., K.E. Schuebel, A.A. Ostrom, J.S. Gutkind, and
X.R. Bustelo. 1997. Phosphotyrosine-dependent activation
of Rac-1 GDP/GTP exchange by the vav proto-oncogene
product. Nature. 385:169–172.
13. Han, J., B. Das, W. Wei, L. Van Aelst, R.D. Mosteller, R.
Khosravi-Far, J.K. Westwick, C.J. Der, and D. Broek. 1997.
Lck regulates Vav activation of members of the Rho family
of GTPases. Mol. Cell. Biol. 17:1346–1353.
14. Adams, J.M., H. Houston, J. Allen, T. Lints, and R. Harvey.
1992. The hematopoietically expressed vav proto-oncogene
shares homology with the dbl GDP-GTP exchange factor,
the bcr gene and a yeast gene (CDC24) involved in cytoskele-
tal organization. Oncogene. 7:611–618.
15. Crespo, P., X.R. Bustelo, D.S. Aaronson, O.A. Coso, M.
Lopez-Barahona, M. Barbacid, and J.S. Gutkind. 1996. Rac-1
dependent stimulation of the JNK/SAPK signaling pathway
by Vav. Oncogene. 13:455–460.
16. Olson, M.F., N.G. Pasteris, J.L. Gorski, and A. Hall. 1996.
Faciogenital dysplasia protein (FGD1) and Vav, two related
proteins required for normal embryonic development, are up-
stream regulators of Rho GTPases. Curr. Biol. 6:1628–1633.
17. Tapon, N., and A. Hall. 1997. Rho, Rac and CDC42 GTPases
regulate the organization of the actin cytoskeleton. Curr.
Opin. Cell Biol. 9:86–92.
18. Coso, O.A., M. Chiariello, J.-C. Yu, H. Teramoto, P. Crespo,
N. Xu, T. Miki, and J.S. Gutkind. 1995. The small GTP-
binding proteins Rac1 and Cdc42 regulate the activity of the
JNK/SAPK signaling pathway. Cell. 81:1137–1146.
19. Hill, C.S., J. Wynne, and R. Treisman. 1995. The Rho fam-
ily of GTPases RhoA, Rac1, and CDC42Hs regulate tran-
scriptional activation by SRF. Cell. 81:1159–1170.
20. Perona, R., S. Montaner, L. Saniger, I. Sanchez-Perez, R.
Bravo, and J.C. Lacal. 1997. Activation of the nuclear factor-
kB by Rho, CDC42 and Rac-1 proteins. Genes Dev. 11:
463–475.
21. Teramoto, H., O.A. Coso, H. Miyata, T. Igishi, T. Miki, and
J.S. Gutkind. 1996. Signaling from the small GTP-binding
proteins Rac1 and Cdc42 to the c-jun N-terminal kinase/
stress activated protein kinase pathway. J. Biol. Chem. 271:
27225–27228.
22. Chou, M.M., and J. Blenis. 1996. The 70 kDa S6 kinase
complexes with and is activated by the Rho family G pro-
teins Cdc42 and Rac1. Cell. 85:573–583.558 Regulation of Cell-mediated Cytotoxicity by the Vav–Rac1 Pathway
23. Lamarche, N., N. Tapon, L. Stowers, P.D. Burbelo, P. As-
penstrom, T. Bridges, J. Chant, and A. Hall. 1996. Rac and
Cdc42 induce actin polymerization and G1 cell cycle pro-
gression independently of p65PAK and the JNK/SAPK MAP
kinase cascade. Cell. 87:519–529.
24. Khosravi-Far, R., P.A. Solski, G.J. Clark, M.S. Kinch, and
C.J. Der. 1995. Activation of Rac1, RhoA, and mitogen-
activated protein kinases is required for Ras transformation.
Mol. Cell. Biol. 15:6443–6453.
25. Qiu, R.-G., D. Chen, D. Kirn, F. McCormick, and M. Sy-
mons. 1995. An essential role for Rac in Ras transformation.
Nature. 374:457–459.
26. Qiu, R.-G., D. Chen, F. McCormick, and M. Symons.
1995. A role for Rho in Ras transformation. Proc. Natl. Acad.
Sci. USA. 92:11781–11785.
27. Westwick, J.K., Q.T. Lambert, G.J. Clark, M. Symons, L. Van
Aelst, R.G. Pestell, and C.J. Der. 1997. Rac regulation of trans-
formation, gene expression, and actin organization by multiple,
PAK-independent pathways. Mol. Cell. Biol. 17:1324–1335.
28. Guillemot, J.-C., P. Montcourrier, E. Vivier, J. Davoust, and
P. Chavrier. 1997. Selective control of membrane ruffling
and actin plaque assembly by the Rho GTPases Rac1 and
CDC42 in FceRI-activated rat basophilic leukemia (RBL-
2H3) cells. J. Cell Sci. 110:2215–2225.
29. Cox, D., P. Chang, Q. Zhang, P.G. Reddy, G.M. Bokoch,
and S. Greenberg. 1997. Requirements for both Rac1 and
CDC42 in membrane ruffling and phagocytosis in leuko-
cytes.  J. Exp. Med. 186:1487–1494.
30. Hackam, D.J., O.D. Rotstein, A. Schreiber, W.J. Zhang, and
S. Grinstein. 1997. Rho is required for the initiation of cal-
cium signaling and phagocytosis by Fcg receptors in mac-
rophages. J. Exp. Med. 186:955–966.
31. Laudanna, C., J.J. Campbell, and E.C. Butcher. 1996. Role
of chemoattractant-activated leukocyte adhesion through in-
tegrins. Science. 271:981–983.
32. Allen, W.E., G.E. Jones, J.W. Pollard, and A.J. Ridley. 1997.
Rho, Rac and Cdc42 regulate actin organization and cell ad-
hesion in macrophages. J. Cell Sci. 110:707–720.
33. Lang, P., L. Guizani, I. Vitte-Mony, R. Stancou, O.
Dorseuil, G. Gacon, and J. Bertoglio. 1992. ADP-ribosyla-
tion of the ras-related, GTP-binding protein RhoA inhibits
lymphocyte-mediated cytotoxicity. J. Biol. Chem. 267:
11677–11680.
34. Stowers, L., D. Yelon, L.J. Berg, and J. Chant. 1995. Regula-
tion of the polarization of T cells towards antigen-presenting
cells by Ras-related GTPase CDC42. Proc. Natl. Acad. Sci.
USA. 92:5027–5031.
35. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Im-
munol. 47:187–376.
36. Brumbaugh, K.M, B.A. Binstadt, D.D. Billadeau, R.A.
Schoon, C.J. Dick, R.M. Ten, and P.J. Leibson. 1997. Func-
tional role for Syk tyrosine kinase in NK cell–mediated natu-
ral cytotoxicity. J. Exp. Med. 186:1965–1974.
37. Einspahr, K.J., R.T. Abraham, B.A. Binstadt, Y. Uehara, and
P.J. Leibson. 1991. Tyrosine phosphorylation provides an
early and requisite signal for the activation of natural killer
cell cytotoxic function. Proc. Natl. Acad. Sci. USA. 88:6279–
6283.
38. O’Shea, J.J., D.W. McVicar, D.B. Kuhns, and J.R. Ortaldo.
1992. A role for protein tyrosine kinase activity in natural cy-
totoxicity as well as antibody-dependent cellular cytotoxicity.
J. Immunol. 148:2497–2502.
39. Vivier, E., P. Morin, C. O’Brien, B. Druker, S.F. Schloss-
man, and P. Anderson. 1991. Tyrosine phosphorylation of
the FcgRIII(CD16) z complex in human natural killer cells.
Induction by antibody-dependent cytotoxicity but not by
natural killing. J. Immunol. 146:206–210.
40. Perez-Villar, J.J., L. Melero, A. Rodriguez, M. Carretero, J.
Aramburu, S. Sivori, A.M. Orengo, A. Moretta, and M.
Lopez-Botet. 1995. Functional ambivalence of the kp43
(CD94) NK cell-associated surface antigen. J. Immunol. 154:
5779–5788.
41. Perussia, B., and G. Trinchieri. 1984. Antibody 3G8, specific
for the human neutrophil Fc receptor, reacts with natural
killer cells. J. Immunol. 132:1410–1415.
42. Windebank, K.P., R.T. Abraham, G. Powis, R.A. Olsen, T.J.
Barna, and P.J. Leibson. 1988. Signal transduction during hu-
man natural killer cell activation: inositol phosphate generation
and regulation by cyclic AMP. J. Immunol. 141:3951–3957.
43. Chakrabarti, S., K. Brachling, and B. Moss. 1985. Vaccinia
virus expression vector: coexpression of beta-galactosidase
provides visual screening of recombinant virus plaques. Mol.
Cell. Biol. 5:3403–3409.
44. Ting, A.T., C.J. Dick, R.A. Schoon, L.M. Karnitz, R.T.
Abraham, and P.J. Leibson. 1995. Interaction between lck
and syk family tyrosine kinases in Fcg receptor-initiated acti-
vation of natural killer cells. J. Biol. Chem. 270:16415–16421.
45. Siliciano, R.F., J.C. Pratt, R.E. Schmidt, J. Ritz, and E.L.
Reinherz. 1985. Activation of cytotoxic T lymphocyte and
natural killer cell function through the T11 sheep erythrocyte
binding protein. Nature. 317:428–430.
46. Kaufman, D.S., R.S. Schoon, M.J. Robertson, and P.J. Leib-
son. 1995. Inhibition of selective signaling events in natural
killer cells recognizing major histocompatibility complex class
I. Proc. Natl. Acad. Sci. USA. 92:6484–6488.
47. Bonnema, J.D., L.M. Karnitz, R.A. Schoon, R.T. Abraham,
and P.J. Leibson. 1994. Fc receptor stimulation of phosphati-
dylinositol 3-kinase in natural killer cells is associated with
protein kinase C–independent granule release and cell-medi-
ated cytotoxicity. J. Exp. Med. 180:1427–1435.
48. Brumbaugh, K.M., J.J. Perez-Villar, C.J. Dick, R.A. Schoon,
M. Lopez-Botet, and P.J. Leibson. 1996. Clonotypic differ-
ences in signaling from CD94 (kp43) on NK cells leads to di-
vergent cellular responses. J. Immunol. 157:2804–2812.
49. Darzynkiewicz, Z., and J. Kapuscinski. 1990. Acridine orange:
a versatile probe of nucleic acids and other cell constituents. In
Flow Cytometry and Sorting, 2nd ed. M.R. Melamed, T.
Lindmo, and M.L. Mendelsohn, editors. Wiley-Liss, Inc.,
New York. 291–314.
50. Katzav, S., M. Sutherland, G. Packham, T. Yi, and A. Weiss.
1994. The protein tyrosine kinase ZAP-70 can associate with
the SH2 domain of proto-Vav. J. Biol. Chem. 269:32579–32585.
51. Teramoto, H., P. Salem, K.C. Robbins, X.R. Bustelo, and
J.S. Gutkind. 1997. Tyrosine phosphorylation of the vav
proto-oncogene product links FceRI to the Rac1-JNK path-
way. J. Biol. Chem. 272:10751–10755.
52. Cone, J.C., Y. Lu, J.M. Trevillyan, J.M. Bjorndahl, and C.A.
Phillips. 1993. Association of the p56lck protein tyrosine ki-
nase with the FcgRIIIA/CD16 complex in human natural
killer cells. Eur. J. Immunol. 23:2488–2497.
53. Pignata, C., K.V.S. Prasad, M.J. Robertson, H. Levine, C.E.
Rudd, and J. Ritz. 1993. FcgRIIIA-mediated signaling in-
volves src-family lck in human natural killer cells. J. Immunol.
151:6794–6800.
54. Salcedo, T.W., T. Kurosaki, P. Kanakaraj, J.V. Ravetch, and
B. Perussia. 1993. Physical and functional association of p56lck559 Billadeau et al.
with the FcgRIIIA (CD16) in natural killer cells. J. Exp.
Med. 177:1475–1480.
55. Stahls, A., G.E. Liwszye, C. Couture, T. Mustelin, and L.C.
Anderson. 1994. Triggering of human natural killer cells
through CD16 induces tyrosine phosphorylation of the p72syk
kinase. Eur. J. Immunol. 24:2491–2496.
56. Ting, A.T., L.M. Karnitz, R.A. Schoon, R.T. Abraham, and
P.J. Leibson. 1992. Fcg receptor activation induces the ty-
rosine phosphorylation of both phospholipase C (PLC)-g1
and PLC-g2 in natural killer cells. J. Exp. Med. 176:1751–
1755.
57. Vivier, E., A.J. da Silva, M. Ackerly, H. Levine, C.E. Rudd,
and P. Anderson. 1993. Association of a 70-kDa tyrosine
phosphoprotein with the CD16:z:g complex expressed in
human natural killer cells. Eur. J. Immunol. 23:1872–1876.
58. Songyang, Z., S.E. Shoelson, J. McGlade, P. Olivier, T.
Pawson, X.R. Bustelo, M. Barbacid, H. Sabe, H. Hanafusa,
T. Yi, et al. 1994. Specific motifs recognized by the SH2 do-
mains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and
Vav. Mol. Cell. Biol. 14:2777–2785.
59. Deckert, M., S. Tartare-Deckert, C. Couture, T. Mustelin,
and A. Altman. 1996. Functional and physical interactions of
Syk family kinases with the Vav proto-oncogene product.
Immunity. 5:591–604.
60. Wu, J., D.G. Motto, G.A. Koretzky, and A. Weiss. 1996.
Vav and SLP-76 interact and functionally cooperate in IL-2
gene activation. Immunity. 4:593–602.
61. Wu, J., Q. Zhao, T. Kurosaki, and A. Weiss. 1997. The Vav
binding site (Y315) in ZAP-70 is critical for antigen recep-
tor–mediated signal transduction. J. Exp. Med. 185:1877–
1882.
62. Katzav, S. 1993. Single point mutations in the SH2 domain
impair the transforming potential of vav and fail to activate
proto-vav. Oncogene. 8:1757–1763.
63. Wu, J., S. Katzav, and A. Weiss. 1995. A functional T-cell
receptor signaling pathway is required for p95vav activity.
Mol. Cell. Biol. 15:4337–4346.
64. Castresana, J., and M. Saraste. 1995. Does Vav bind to F-actin
through a CH domain? FEBS Lett. 374:149–151.
65. Huby, R.D., G.W. Carlile, and S.C. Ley. 1995. Interactions
between the protein-tyrosine kinase ZAP-70, the proto-
oncogene Vav, and tubulin in Jurkat T cells. J. Biol. Chem.
270:30241–30244.
66. Hobert, O., J.W. Schilling, M.C. Beckerle, A. Ulrich, and B.
Jallal. 1996. SH3 domain-dependent interaction of the proto-
oncogene product Vav with the focal contact protein zyxin.
Oncogene. 12:1577–1581.
67. Fischer, K.-D., A. Zmuldzinas, S. Gardner, M. Barbacid, A.
Bernstein, and C. Guidos. 1995. Defective T-cell receptor
signalling and positive selection of Vav-deficient CD41
CD81 thymocytes. Nature. 374:474–477.
68. Tarakhovsky, A., M. Turner, S. Schaal, P.J. Mee, L.P.
Duddy, K. Rajewsky, and V.L. Tybulewicz. 1995. Defective
antigen receptor-mediated proliferation of B and T cells in
the absence of Vav. Nature. 374:467–470.
69. Zhang, R., F.W. Alt, L. Davidson, S.H. Orkin, and W. Swat.
1995. Defective signaling through the T- and B-cell antigen
receptors in lymphoid cells lacking the vav proto-oncogene.
Nature. 374:470–473.
70. Turner, M., J.P. Mee, A.E. Walters, M.E. Quinn, A.L. Mel-
lor, R. Zamoyska, and V.L.J. Tybulewicz. 1997. A require-
ment for the Rho-family GTP exchange factor Vav in posi-
tive and negative selection of thymocytes. Immunity. 7:451–460.
71. Chow, S.C., J. Ng, C. Nordstedt, B.B. Fredholm, and M.
Jondal. 1988. Phosphoinositide breakdown and evidence for
protein kinase C involvement during human NK killing.
Cell. Immunol. 114:96–103.
72. Chong, L.D., A. Traynor-Kaplan, G.M. Bokoch, and M.A.
Schwartz. 1994. The small GTP-binding protein Rho regu-
lates a phosphatidylinositol 4-phosphate 5-kinase in mamma-
lian cells. Cell. 79:507–513.
73. Ren, X.D., G.M. Bokoch, A. Traynor-Kaplan, G.H. Jen-
kins, R.A. Anderson, and M.A. Schwartz. 1996. Physical as-
sociation of the small GTPase Rho with a 68-kDa phosphati-
dylinositol 4-phosphate 5-kinase in Swiss 3T3 cells. Mol.
Cell. Biol. 7:435–442.
74. Tolias, K.F., L.C. Cantley, and C.L. Carpenter. 1995. Rho
family GTPases bind to phosphoinositide kinases. J. Biol.
Chem. 270:17656–17659.
75. Azzoni, L., M. Kamoun, T.W. Salcedo, P. Kanakaraj, and B.
Perussia. 1992. Stimulation of FcgRIIIA results in phospholi-
pase C-g1 tyrosine phosphorylation and p56lck activation. J.
Exp. Med. 176:1745–1750.
76. Fedorov, A.A., K.A. Magnus, M.H. Graupe, E.E. Lattman,
T.D. Pollard, and S.C. Almo. 1994. X-ray structures of iso-
forms of the actin-binding protein profilin that differ in their
affinity for phosphatidylinositol phosphates. Proc. Natl. Acad.
Sci. USA. 91:8636–8640.
77. Fukami, K., N. Sawada, T. Endo, and T. Takenawa. 1996.
Identification of a phosphatidylinositol 4,5-bisphosphate-
binding site in chicken skeletal muscle alpha-actinin. J. Biol.
Chem. 271:2646–2650.
78. Hyvonen, M., M.J. Macias, M. Nilges, H. Oschkinat, M. Sa-
raste, and M. Wilmannus. 1995. Structure of the binding site
for inositol phosphates in a PH domain. EMBO (Eur. Mol.
Biol. Organ.) J. 14:4676–4685.
79. Nobes, C.D., and A. Hall. 1995. Rho, rac and cdc42 GTPases
regulate the assembly of multimolecular focal complexes asso-
ciated with actin stress fibers, lamellipodia, and filopodia.
Cell. 81:53–62.
80. Ridley, A.J., H.F. Paterson, C.L. Johnston, D. Diekmann,
and A. Hall. 1992. The small GTP-binding protein rac regu-
lates growth factor-induced membrane ruffling. Cell. 70:
401–410.
81. Aepfelbacher, M., F. Vauti, P.C. Weber, and J.A. Glomset.
1994. Spreading of differentiating human monocytes is asso-
ciated with a major increase in membrane-bound CDC42.
Proc. Natl. Acad. Sci. USA. 91:4263–4267.
82. Aepfelbacher, M., M. Essler, E. Huber, A. Czech, and P.C.
Weber. 1996. Rho is a negative regulator of human mono-
cyte spreading. J. Immunol. 157:5070–5075.
83. Braga, V.M.M., L.M. Mahesky, A. Hall, and N.A. Hotchin.
1997. The small GTPases Rho and Rac are required for the
establishment of cadherin-dependent cell-cell contacts. J. Cell
Biol. 137:1421–1431.
84. Kohl, S., T.A. Springer, F.C. Schmalstieg, L.S. Loo, and
D.C. Anderson. 1984. Defective natural killer cytotoxicity
and polymorphonuclear leukocyte antibody-dependent cel-
lular cytotoxicity in patients with LFA-1/OKM-1 deficiency.
J. Immunol. 133:2972–2978.
85. Shier, P., G. Otulakowski, K. Ngo, J. Panakos, E. Chour-
mouzis, L. Christjansen, C.Y. Lauk, and W.-P. Fung-Leung.
1996. Impaired immune responses toward alloantigens and
tumor cells but normal thymic selection in mice deficient in
the b2 integrin leukocyte function-associated antigen-1. J.
Immunol. 157:5375–5386.